Valuation: Black Diamond Therapeutics, Inc.

Market Cap 105M 92.57M 85.21M 79.4M 150M 10.02B 153M 1.02B 397M 4.92B 396M 387M 17.12B P/E 2026 *
-2.84x
P/E 2027 * -1.83x
Enterprise Value 105M 92.57M 85.21M 79.4M 150M 10.02B 153M 1.02B 397M 4.92B 396M 387M 17.12B EV / Sales 2026 *
19x
EV / Sales 2027 * -
Free-Float
99.35%
Yield 2026 *
-
Yield 2027 * -
1 day+5.98%
1 week+14.41%
Current month+5.14%
1 month-10.78%
3 months-18.62%
6 months-21.89%
Current year-19.96%
1 week 1.68
Extreme 1.68
2.02
1 month 1.6
Extreme 1.6
2.21
Current year 1.6
Extreme 1.6
3.97
1 year 1.6
Extreme 1.6
4.94
3 years 1.2
Extreme 1.195
7.66
5 years 1.18
Extreme 1.18
12.1
10 years 1.18
Extreme 1.18
46.25
Manager TitleAgeSince
Chief Executive Officer 62 16/09/2023
Chief Tech/Sci/R&D Officer 51 11/08/2021
Director of Finance/CFO 41 07/10/2024
Director TitleAgeSince
Director/Board Member 61 01/03/2017
Director/Board Member 47 01/12/2019
Director/Board Member 50 01/12/2018
Date Insider Type Main position Quantity % Market Cap.
26/06Free

Director

40,000 0.0698%
26/06Free

Director

40,000 0.0698%
26/06Free

Director

40,000 0.0698%
Change 5-day change 1-year change 3-year change Capi.($)
+6.25%+14.41%-25.19%-58.53% 105M
+4.01%+5.58%+76.44%+136.23% 56.21B
-3.12%+5.11%+71.57%+94.67% 55.38B
+3.75%+8.52%-9.78%-9.41% 23.75B
+2.92%+5.14%+11.81%+429.35% 23.19B
+3.64%+10.54%+39.81%-4.50% 18.14B
+4.11%+8.89%+44.60%-27.73% 16.84B
+2.57%+20.26%+181.98%+355.99% 15.86B
+3.18%+4.83%+25.96%+191.69% 13.56B
+7.20%+10.70%+42.91% - 12.97B
Average +3.42%+6.42%+46.01%+123.08% 23.6B
Weighted average by Cap. +2.21%+6.09%+57.48%+135.96%

Financials

2026 *2027 *
Net sales 5.56M 4.88M 4.49M 4.18M 7.89M 528M 8.05M 54M 20.92M 259M 20.86M 20.41M 902M -
Net income -40.47M -35.54M -32.71M -30.48M -57.48M -3.85B -58.65M -393M -152M -1.89B -152M -149M -6.57B -70.04M -61.5M -56.61M -52.75M -99.48M -6.66B -102M -681M -264M -3.27B -263M -257M -11.38B
Net Debt - -
Logo Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Employees
21
Date Price Change Volume
03/07/26 USD 1.945 +5.71% 553,981
01/07/26 USD 1.840 -0.54% 4,375,137
30/06/26 USD 1.850 +5.71% 1,883,436
29/06/26 USD 1.750 +2.34% 1,154,453
26/06/26 USD 1.710 +0.59% 8,578,830
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.840USD
Average target price
9.857USD
Spread / Average Target
+435.71%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BDTX Stock